Skip to main content
TipRanks
Go Ultimate75% OFF

RaQualia Pharma Inc. (4579) AI Stock Analysis

1 Followers
JP:4579

RaQualia Pharma Inc.

(TSE/TYO:4579)

Select Model
Rating:64Neutral
Price Target:JPY 691.00â–¼(-6.37% Downside)
Action:reiterated
Date:11/16/26

The overall score of 64 reflects a company in a significant financial recovery phase, which is the primary driver of value. Strong cash flow generation and a return to profitability are major positives. However, this is balanced by a high valuation multiple that prices in continued success, a long-term bearish technical trend, and the risk associated with newly acquired debt and historically volatile financials.

Positive Factors
Profitability reboundThe return to profitability alongside a roughly 3.1x revenue increase indicates materially improved operating performance in the latest period. Positive EBIT and net margins provide a stronger base for reinvestment and demonstrate that recent commercial or licensing activity is translating into earnings.
Negative Factors
Earnings volatilityThe shift from profits in 2021–2022 to losses in 2023–2024 shows that earnings are not yet consistently predictable. Such volatility may reflect the timing of milestones or other one-off income, making it harder to forecast sustainable profitability and plan investment over several periods.

RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)

-50%-25%0%25%50%75%100%125%150%JP:4579+19.03%EWJ+16.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 16.82B
Dividend Yield
―
Average Volume (3M)
175.16K
Price to Earnings (P/E)
44.7
Beta (1Y)
1.14
Revenue Growth
31.84%
EPS Growth
―
Country
Japan
Employees
85
Sector
General
Sector Strength
55
Industry
Biotechnology

RaQualia Pharma Inc. Business Overview & Revenue Model

Company Description

RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegopraza...

RaQualia Pharma Inc. Financial Statement Overview

Summary

RaQualia Pharma shows a strong financial turnaround with surging revenue, a return to profitability, and robust cash flow generation. High gross margins above 80% are a key strength, though thin single-digit net margins and a recent increase in leverage to 0.33 debt-to-equity temper the score.

Income Statement

72Positive

Balance Sheet

65Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.02B3.98B3.11B1.90B2.92B2.78B
Gross Profit3.23B3.27B2.48B1.66B2.69B2.46B
EBITDA1.06B985.17M188.27M-111.80M1.00B1.02B
Net Income348.52M273.12M-495.03M-323.66M723.39M755.79M
Balance Sheet
Total Assets10.70B10.51B9.66B6.93B6.26B5.23B
Cash, Cash Equivalents and Short-Term Investments4.81B3.24B3.34B3.76B3.93B2.66B
Total Debt2.53B2.90B3.45B432.02M222.34M39.07M
Total Liabilities2.91B3.62B4.08B809.83M760.67M446.19M
Stockholders Equity7.79B6.90B5.57B6.12B5.50B4.79B
Cash Flow
Free Cash Flow717.72M-423.98M84.24M-940.80M1.45B260.61M
Operating Cash Flow746.39M-356.63M180.94M-718.60M1.48B366.03M
Investing Cash Flow-298.84M124.32M-3.67B-135.37M-47.65M-279.25M
Financing Cash Flow803.03M380.26M2.98B793.45M-29.56M-16.44M

RaQualia Pharma Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price738.00

Price Trends

50DMA602.92Positive
100DMA550.40Positive
200DMA681.20Negative

Market Momentum

MACD13.84Negative
RSI54.06Neutral
STOCH84.90Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Positive. The current price of 738.00 is above the 20-day moving average (MA) of 630.10, above the 50-day MA of 602.92, and above the 200-day MA of 681.20, indicating a neutral trend. The MACD of 13.84 indicates Negative momentum. The RSI at 54.06 is Neutral, neither overbought nor oversold. The STOCH value of 84.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4579.

RaQualia Pharma Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4579 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4579JP:457964NeutralJPY 16.82B44.72――31.84%―
JP:4565JP:456563NeutralJPY 167.91B-30.86-8.51%―23.72%12.48%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4588JP:458850NeutralJPY 248.42B-146.15――1748.97%35.11%
JP:4587JP:458748NeutralJPY 138.26B-47.73-5.85%―14.25%50.07%
JP:4563JP:456342NeutralJPY 11.13B-1.91-558.92%―19.67%84.06%
JP:4571JP:457141NeutralJPY 6.10B-4.20-39.57%―48.92%-46.91%

* General Sector Average

Performance Comparison

0%200%400%600%JP:4579JP:4563JP:4587JP:4565JP:4571JP:4588Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4579 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4579RaQualia Pharma Inc.738.00175.0031.08%
JP:4563AnGes 25.00-49.00-66.22%
JP:4587Peptidream 1089.00-587.00-35.02%
JP:4565Sosei Group Corporation1807.00967.00115.12%
JP:4571NanoCarrier Co., Ltd.68.00-81.00-54.36%
JP:4588Oncolys BioPharma, Inc.8080.007040.00676.92%

RaQualia Pharma Inc. Corporate Events

RaQualia Pharma Reports Nine-Month Results Through September 2026

Nov 13, 2026

RaQualia Pharma Inc. reported consolidated net sales of ¥2.35 billion for the nine months ended September 30, 2026, up 1.7% from a year earlier. Operating loss narrowed to ¥238 million from ¥344 million, ordinary loss narrowed to ¥261 million from ¥4...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026